We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Saniona AB (SANION) NPV

Sell:2.77 SEK Buy:2.80 SEK Change: 0.04 SEK (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.77 SEK
Buy:2.80 SEK
Change: 0.04 SEK (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:2.77 SEK
Buy:2.80 SEK
Change: 0.04 SEK (1.42%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Saniona AB is a Sweden-based company active in the field of biotechnology. It operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The Company develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The Company is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.

Contact details

Address:
Smedeland 26B
GLOSTRUP
2600
Denmark
Telephone:
+ ()
Website:
https://saniona.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SANION
ISIN:
SE0005794617
Market cap:
314.40 million SEK
Shares in issue:
111.24 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Thomas Feldthus
    Chief Executive Officer
  • Anita Milland
    Chief Financial Officer
  • Palle Christophersen
    Executive Vice President - Research
  • Karin Nielsen
    Chief Scientific Officer
  • Janus Larsen
    Chief Development Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.